Men with high-grade prostate cancer may be particularly interested in important new research findings that demonstrate the benefits of LDR brachytherapy–also known as seed implant— when used in combination with external beam radiation therapy (EBRT).
Published in the Journal of the American Medical Association, the large study reflects findings of research underway at Prostate Cancer Foundation of Chicago (PCFC).
LDR Brachytherapy ‘Boost’ Improves Outcomes for Patients with High-Grade Prostate Cancer
Researchers at 12 specialty centers were led by Amar U. Kishan, M.D., University of California Los Angeles. They analyzed prostate cancer treatment outcomes for over 1,809 patients with Gleason scores of 9 and 10—men more likely to have their cancer spread to other organs. The study showed that men who received low dose rate (LDR) brachytherapy as a boost to external beam radiation therapy (EBRT), had better clinical outcomes than men undergoing either radical prostatectomy surgery (removal of the entire prostate gland) or EBRT alone.
Men in both external beam radiation groups also received androgen deprivation hormone therapy, which is prescribed commonly to slow the growth of cancerous tissue and/or reduce the size of the prostate gland pre-treatment..
Mortality Rate Reductions
According to the study, adding LDR brachytherapy to EBRT resulted in less prostate cancer deaths and less spread of cancer beyond the prostate. More exactly, EBRT with seed implant resulted in lower 5-year prostate cancer-specific mortality; lower 5-year rate of distant metastasis and lower all-cause mortality within 7.5 years of follow-up, when compared to both prostate removal surgery and to EBRT alone.
Research by Prostate Cancer Foundation of Chicago
Prostate Cancer Foundation of Chicago (PCFC) strives to educate men about their range of prostate cancer treatment options. Working hand-in-hand with Chicago Prostate Cancer Center, PCFC is currently tracking outcomes for men treated with combination therapy—men receiving LDR brachytherapy after prescribed sessions of external beam radiation. PCFC’s findings, along with those reported by UCLA, will educate physicians treating patients with high-grade prostate cancer, while informing men seeking treatment options.
Contact Michelle Braccioforte, Director of Research and Education, at 630-654-2515, to learn more about Prostate Cancer Foundation of Chicago and our mission to improve quality of care and quality of life through clinical research, patient support programs and professional and public education. Details about PCFC Informational Support Group meetings, Free Prostate Cancer Screening and educational outreach for your organization or corporate wellness program are also available at www.chicagoprostatefoundation.org.